Literature DB >> 1946315

Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines.

T D Mullins1, H F Kern, R S Metzgar.   

Abstract

The differentiation effects of sodium butyrate were examined in a series of human pancreatic adenocarcinoma cell lines: Panc-1, a poorly differentiated cell line; HPAF, a pleomorphic cell line isolated in this laboratory; and two clones of the parental HPAF cell line, well-differentiated CD11 and less-differentiated CD18. Incubation with 2 mM sodium butyrate induced a dramatic decrease in cell proliferation and saturation densities in culture and an increase in alkaline phosphatase activity. Of particular interest, incubation with sodium butyrate also caused a number of morphologic alterations in these cells, attributed to an induction of secretory differentiation. Following sodium butyrate treatment, CD18 cells were virtually indistinguishable from the more highly differentiated CD11 cells as evidenced by an increase in the number of profiles of rough endoplasmic reticulum and of Golgi. Intercellular and intracytoplasmic lumens, whose appearance is quite common in CD11 cells but nonexistent in untreated CD18 cells, appeared in these cells following only 5 days of sodium butyrate treatment. An increase in the cytoplasmic secretory elements was also observed in sodium butyrate-treated Panc-1 cells; however, lumen formation never occurred in these cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1946315     DOI: 10.1097/00006676-199109000-00012

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

Review 1.  Current evidence for histone deacetylase inhibitors in pancreatic cancer.

Authors:  Ioannis Koutsounas; Constantinos Giaginis; Efstratios Patsouris; Stamatios Theocharis
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

2.  Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines.

Authors:  N Egawa; B Maillet; B VanDamme; J De Grève; G Klöppel
Journal:  Virchows Arch       Date:  1996-09       Impact factor: 4.064

3.  Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer.

Authors:  H Saito; S Tada; H Ebinuma; S Tsunematsu; T Kagawa; N Kumagai; Y Inagaki; T Watanabe; K Tsuchimoto; T Morizane
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

4.  Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer.

Authors:  Suhasini Joshi; Eric Cruz; Satyanarayana Rachagani; Sushovan Guha; Randall E Brand; Moorthy P Ponnusamy; Sushil Kumar; Surinder K Batra
Journal:  Mol Oncol       Date:  2016-04-29       Impact factor: 6.603

5.  The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.

Authors:  Priya Pai; Satyanarayana Rachagani; Imayavaramban Lakshmanan; Muzafar A Macha; Yuri Sheinin; Lynette M Smith; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Mol Oncol       Date:  2015-10-19       Impact factor: 6.603

Review 6.  Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma.

Authors:  Borbála Kiss; Edit Mikó; Éva Sebő; Judit Toth; Gyula Ujlaki; Judit Szabó; Karen Uray; Péter Bai; Péter Árkosy
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

Review 7.  Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients.

Authors:  Heidelinde Sammallahti; Arto Kokkola; Sama Rezasoltani; Reza Ghanbari; Hamid Asadzadeh Aghdaei; Sakari Knuutila; Pauli Puolakkainen; Virinder Kaur Sarhadi
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 8.  Impact of posttranslational modifications in pancreatic carcinogenesis and treatments.

Authors:  Nianhong Chen; Qiaoqiao Zheng; Guoqing Wan; Feng Guo; Xiaobin Zeng; Ping Shi
Journal:  Cancer Metastasis Rev       Date:  2021-08-03       Impact factor: 9.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.